Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
ConditionTriple Negative Breast Cancer
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18-70
SponsorRenJi Hospital
About this trial
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Eligibility criteria
Qualifiers
Female, Aged ≥18 and ≤70 years
Histologically confirmed triple negative breast cancer (ER<10%, PR<10%, and HER2 negative)
Subjects with at least one evaluable lesion
ECOG 0-1
Disqualifiers
Metastatic disease (Stage IV)
Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test;Female patients of childbearing age that are reluctant to take effective contraceptive measures throughout the trial period
Trial design
Treatments tested in this trial
- Serplulimab
- Paclitaxel
- Carboplatin
Treatment groups
46 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov